FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1890197789> ?p ?o ?g. }

• W1890197789 abstract "ABSTRACT Aim: Increased expression of excision repair cross-complementing group 1 (ERCC1) protein might be associated with platinum resistance in NSCLC, based on retrospective and meta-analyses findings. We conducted the first ever trial to prospectively evaluate ERCC1 as a predictive marker: to assess whether non-platinum therapy is superior to platinum for ERCC1 + ve, and non-inferior for ERCC1-ve tumors. Methods: Pts with stage IIIB/IV NSCLC (chemo-naive, tissue biopsy available, ECOG PS 0-1) were randomised to receive either platinum-based or non-platinum doublet chemotherapy, after ERCC1 stratification using a recommended monoclonal antibody (clone 8F1) assessed centrally. Pts with squamous (sq) histology had cisplatin/gemcitabine (CG) or paclitaxel/gemcitabine (PG); non-squamous (non-sq) pts had cisplatin/pemetrexed (CP) or paclitaxel/pemetrexed (PP), every 3 wks for up to 6 cycles. Primary endpoint was overall survival (OS). From 2012, we concurrently used another recommended antibody (clone 3F2) specific for XPF/ERCC1 protein complex. Results: 648 pts were recruited from 85 UK centres. Baseline characteristics were balanced for both sq (n = 177) and non-sq (n = 471) pts. Recruitment stopped in 2012 for sq pts because PG OS was inferior to CG, regardless of ERCC1 status: median OS 7.7 vs 11.2 months, HR = 1.54 (95% CI 1.05-2.26, P = 0.03). We stopped accrual in 2013 when main trial objective could not be met for non-sq pts: preliminary OS HR for ERCC1 + ve tumors 1.08 (95%CI 0.75-1.54, P = 0.68), median OS 9.7 (PP) vs 10.9 (CP) months. For ERCC1-ve tumors, HR 0.94 (0.62-1.43, P = 0.79), median OS 9.5 (PP) vs 8.4 (CP) months. HRs using XPF antibody were ERCC1 + ve tumors 1.10 (0.76-1.61, p = 0.61), and ERCC1-ve tumors 1.21 (0.65-2.24, p = 0.54). Findings for progression-free survival were similar. ERCC1 positive rate in non-sq pts was 54% (8F1) or 71% (XPF); 28% of pts had discordant ERCC1 status. Grade 3/4 hematological toxicities were less common with non-platinum therapy: 31% (CG) vs 17% (PG), and 22% (CP) vs 17% (PP). Conclusions: Selecting platinum or non-platinum chemotherapy prospectively based on either of two recommended ERCC1 antibodies in advanced NSCLC did not influence survival. Our prospective data support recent concerns over the reliability of current ERCC1 antibody performance as a predictive biomarker of resistance to platinum-based therapy. Disclosure: All authors have declared no conflicts of interest." @default.
• W1890197789 created "2016-06-24" @default.
• W1890197789 creator A5002621278 @default.
• W1890197789 creator A5003419213 @default.
• W1890197789 creator A5005046457 @default.
• W1890197789 creator A5005554940 @default.
• W1890197789 creator A5010405819 @default.
• W1890197789 creator A5019646420 @default.
• W1890197789 creator A5024423770 @default.
• W1890197789 creator A5028146377 @default.
• W1890197789 creator A5034748028 @default.
• W1890197789 creator A5035278067 @default.
• W1890197789 creator A5037200778 @default.
• W1890197789 creator A5038725960 @default.
• W1890197789 creator A5043504529 @default.
• W1890197789 creator A5045870974 @default.
• W1890197789 creator A5055057910 @default.
• W1890197789 creator A5064779653 @default.
• W1890197789 creator A5068874700 @default.
• W1890197789 creator A5075355104 @default.
• W1890197789 creator A5079204377 @default.
• W1890197789 creator A5089453687 @default.
• W1890197789 date "2014-09-01" @default.
• W1890197789 modified "2023-10-01" @default.
• W1890197789 title "Et: a Randomized, Multicenter, Phase III Trial of Platinum Versus Nonplatinum Chemotherapy, After Ercc1 Stratification, in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (Nsclc)" @default.
• W1890197789 doi "https://doi.org/10.1093/annonc/mdu326.3" @default.
• W1890197789 hasPublicationYear "2014" @default.
• W1890197789 type Work @default.
• W1890197789 sameAs 1890197789 @default.
• W1890197789 citedByCount "0" @default.
• W1890197789 crossrefType "journal-article" @default.
• W1890197789 hasAuthorship W1890197789A5002621278 @default.
• W1890197789 hasAuthorship W1890197789A5003419213 @default.
• W1890197789 hasAuthorship W1890197789A5005046457 @default.
• W1890197789 hasAuthorship W1890197789A5005554940 @default.
• W1890197789 hasAuthorship W1890197789A5010405819 @default.
• W1890197789 hasAuthorship W1890197789A5019646420 @default.
• W1890197789 hasAuthorship W1890197789A5024423770 @default.
• W1890197789 hasAuthorship W1890197789A5028146377 @default.
• W1890197789 hasAuthorship W1890197789A5034748028 @default.
• W1890197789 hasAuthorship W1890197789A5035278067 @default.
• W1890197789 hasAuthorship W1890197789A5037200778 @default.
• W1890197789 hasAuthorship W1890197789A5038725960 @default.
• W1890197789 hasAuthorship W1890197789A5043504529 @default.
• W1890197789 hasAuthorship W1890197789A5045870974 @default.
• W1890197789 hasAuthorship W1890197789A5055057910 @default.
• W1890197789 hasAuthorship W1890197789A5064779653 @default.
• W1890197789 hasAuthorship W1890197789A5068874700 @default.
• W1890197789 hasAuthorship W1890197789A5075355104 @default.
• W1890197789 hasAuthorship W1890197789A5079204377 @default.
• W1890197789 hasAuthorship W1890197789A5089453687 @default.
• W1890197789 hasBestOaLocation W18901977891 @default.
• W1890197789 hasConcept C104317684 @default.
• W1890197789 hasConcept C104451858 @default.
• W1890197789 hasConcept C126322002 @default.
• W1890197789 hasConcept C134935766 @default.
• W1890197789 hasConcept C143998085 @default.
• W1890197789 hasConcept C185592680 @default.
• W1890197789 hasConcept C2776256026 @default.
• W1890197789 hasConcept C2776694085 @default.
• W1890197789 hasConcept C2777240266 @default.
• W1890197789 hasConcept C2778239845 @default.
• W1890197789 hasConcept C2779309665 @default.
• W1890197789 hasConcept C2780258809 @default.
• W1890197789 hasConcept C2780350996 @default.
• W1890197789 hasConcept C2781451048 @default.
• W1890197789 hasConcept C55493867 @default.
• W1890197789 hasConcept C71924100 @default.
• W1890197789 hasConceptScore W1890197789C104317684 @default.
• W1890197789 hasConceptScore W1890197789C104451858 @default.
• W1890197789 hasConceptScore W1890197789C126322002 @default.
• W1890197789 hasConceptScore W1890197789C134935766 @default.
• W1890197789 hasConceptScore W1890197789C143998085 @default.
• W1890197789 hasConceptScore W1890197789C185592680 @default.
• W1890197789 hasConceptScore W1890197789C2776256026 @default.
• W1890197789 hasConceptScore W1890197789C2776694085 @default.
• W1890197789 hasConceptScore W1890197789C2777240266 @default.
• W1890197789 hasConceptScore W1890197789C2778239845 @default.
• W1890197789 hasConceptScore W1890197789C2779309665 @default.
• W1890197789 hasConceptScore W1890197789C2780258809 @default.
• W1890197789 hasConceptScore W1890197789C2780350996 @default.
• W1890197789 hasConceptScore W1890197789C2781451048 @default.
• W1890197789 hasConceptScore W1890197789C55493867 @default.
• W1890197789 hasConceptScore W1890197789C71924100 @default.
• W1890197789 hasLocation W18901977891 @default.
• W1890197789 hasOpenAccess W1890197789 @default.
• W1890197789 hasPrimaryLocation W18901977891 @default.
• W1890197789 isParatext "false" @default.
• W1890197789 isRetracted "false" @default.
• W1890197789 magId "1890197789" @default.
• W1890197789 workType "article" @default.